| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Philogen SpA (MI: PHIL)
PHIL Technical Analysis
4
| As on 15th Jan 2026 PHIL STOCK Price closed @ 21.70 and we RECOMMEND Buy for LONG-TERM with Stoploss of 21.27 & Strong Buy for SHORT-TERM with Stoploss of 18.60 we also expect STOCK to react on Following IMPORTANT LEVELS. |
PHILSTOCK Price
| Open | 21.80 | Change | Price | % |
| High | 21.90 | 1 Day | 0.10 | 0.46 |
| Low | 21.50 | 1 Week | -0.90 | -3.98 |
| Close | 21.70 | 1 Month | -2.30 | -9.58 |
| Volume | 24851 | 1 Year | 2.50 | 13.02 |
| 52 Week High 27.40 | 52 Week Low 17.50 | ||||
MI Italy Most Active Stocks
| TIT | 0.57 | 3.64% |
| TITR | 0.67 | 1.52% |
| SPM | 2.72 | 0.37% |
| ISP | 6.00 | 0.50% |
| ENEL | 9.29 | -0.32% |
| BMPS | 9.20 | -1.60% |
| NEXI | 3.78 | -1.05% |
| ENI | 16.44 | -1.67% |
| A2A | 2.46 | 1.65% |
| STLA | 15.58 | 0.45% |
MI Italy Top Gainers Stocks
MI Italy Top Losers Stocks
| PHIL Daily Charts |
PHIL Intraday Charts |
Whats New @ Bazaartrend |
PHIL Free Analysis |
|
|
PHIL Important Levels Intraday
| RESISTANCE | 22.47 |
| RESISTANCE | 22.22 |
| RESISTANCE | 22.07 |
| RESISTANCE | 21.92 |
| SUPPORT | 21.48 |
| SUPPORT | 21.33 |
| SUPPORT | 21.18 |
| SUPPORT | 20.93 |
PHIL Forecast January 2026
| 4th UP Forecast | 27.96 |
| 3rd UP Forecast | 25.95 |
| 2nd UP Forecast | 24.71 |
| 1st UP Forecast | 23.47 |
| 1st DOWN Forecast | 19.93 |
| 2nd DOWN Forecast | 18.69 |
| 3rd DOWN Forecast | 17.45 |
| 4th DOWN Forecast | 15.44 |
PHIL Weekly Forecast
| 4th UP Forecast | 22.47 |
| 3rd UP Forecast | 22.22 |
| 2nd UP Forecast | 22.07 |
| 1st UP Forecast | 21.92 |
| 1st DOWN Forecast | 21.48 |
| 2nd DOWN Forecast | 21.33 |
| 3rd DOWN Forecast | 21.18 |
| 4th DOWN Forecast | 20.93 |
PHIL Forecast2026
| 4th UP Forecast | 43.48 |
| 3rd UP Forecast | 36.49 |
| 2nd UP Forecast | 32.18 |
| 1st UP Forecast | 27.86 |
| 1st DOWN Forecast | 15.54 |
| 2nd DOWN Forecast | 11.22 |
| 3rd DOWN Forecast | 6.91 |
| 4th DOWN Forecast | -0.08 |
Philogen SpA ( MI Italy Symbol : PHIL )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
PHIL Business Profile
Philogen S.p.A., a biotechnology company, develops biopharmaceuticals for the treatment of angiogenesis-related disorders. The company focuses on developing immunocytokines for oncology and in chronic inflammatory diseases. It is developing NIDLEGYTM (DAROMUN), an immunocytokine product used as a neoadjuvant intralesional treatment for melanoma patients with locoregional disease that is in phase III clinical trial for intralesional application and phase II clinical trial to treat non-melanoma skin cancer; FIBROMUN, a human immunomodulatory product consisting of the human anti-EDB antibody L19 to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and DARLEUKIN (L19IL2), a human immunostimulatory product consisting of the human anti-EDB antibody L19, which is in phase II clinical trial for the treatment of metastatic non-small cell lung cancer. The company is also developing DODEKIN, a human immunostimulatory product that comprises vascular targeting antibody fused to the human cytokine interleukin-12 that is in phase I clinical trial to treat advanced solid carcinomas; DEKAVIL (F8IL10), an anti-inflammatory product, which is in phase 2 clinical trial for the treatment of chronic inflammation; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressing solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial. Philogen S.p.A. was founded in 1996 and is based in Sovicille, Italy. Address: Via Bellaria, 35, Sovicille, SI, Italy, 53018
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service